A randomized, double-blind, double-dummy, placebo-controlled, parallel-group study to assess & compare efficacy & safety of an 8-week treatment with Respimat® inhaler & fluticasone propionate in patients w/asthma inadequately controlled on med. dose ICS.
Description of Research
The aim of this clinical study is to compare the efficacy and safety of three different doses of BI 54903 with fluticasone and so-called placebo (a compound that is identical in appearance to the study medication but does not contain any active ingredient).
Participants in the study suffer from asthma. Patients
with asthma may take part in this study if they are being treated with low to medium doses of an inhaled corticosteroid.